Home / India News / NLEM 2022: Analysts see no major impact pharma companies' growth

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Premium

The bulk of the inclusions in the NLEM 2022 are in the anti-infective category, which constitutes roughly 13 per cent of the domestic market

Sohini Das Mumbai

4 min read Last Updated : Sep 13 2022 | 10:47 PM IST

The latest revision of the National List of Essential Medicines (NLEM) that included 34 new drugs and removed 26 is unlikely to have a noticeable impact on the domestic pharmaceutical market, felt analysts and industry insiders.

The National Pharmaceutical Pricing Authority (NPPA) controls the ceiling prices of medicines included in the NLEM, based on the wholesale price index. These are called scheduled drugs. All other drugs (non-scheduled drugs) are allowed to take up to 10 per cent hikes every year.

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM

Topics : Medicines in India pharmaceutical firms National Pharmaceutical Pricing Authority Cipla NLEM Glenmark Pharmaceuticals Pharma Companies insulin Alkem Labs Pharma sales Health Ministry

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in